Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2-4-2021

Biomarkers associated with blinatumomab outcomes in acute
lymphoblastic leukemia
Andrew H Wei
Josep-Maria Ribera
Richard A Larson
David Ritchie
Armin Ghobadi

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Andrew H Wei, Josep-Maria Ribera, Richard A Larson, David Ritchie, Armin Ghobadi, Yuqi Chen, Abraham
Anderson, Cedric E Dos Santos, Janet Franklin, and Hagop Kantarjian

Leukemia (2021) 35:2220–2231
https://doi.org/10.1038/s41375-020-01089-x

ARTICLE
Acute lymphoblastic leukemia

Biomarkers associated with blinatumomab outcomes in acute
lymphoblastic leukemia
Andrew H. Wei 1 Josep-Maria Ribera2 Richard A. Larson 3 David Ritchie4 Armin Ghobadi5 Yuqi Chen6
Abraham Anderson6 Cedric E. Dos Santos7 Janet Franklin6 Hagop Kantarjian8
●

●

●

●

●

●

●

●

●

1234567890();,:

1234567890();,:

Received: 3 September 2019 / Revised: 8 August 2020 / Accepted: 31 October 2020 / Published online: 4 February 2021
© The Author(s) 2021. This article is published with open access

Abstract
This study aimed to identify biomarkers for clinical outcomes in a phase 3 clinical study of blinatumomab or chemotherapy
in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Patients were randomized 2:1 to receive blinatumomab, a BiTE® therapy, for 4 weeks (9 μg/day cycle 1 week 1, 28 μg/day
thereafter) every 6 weeks, or chemotherapy. Baseline blood samples were evaluated to identify biomarkers prognostic (both
treatment groups) or predictive (either treatment groups) for overall survival, event-free survival, hematologic remission,
minimal residual disease (MRD) response, duration of response, or adverse events. Baseline values were balanced between
treatment groups. Prognostic biomarkers were platelets, tumor burden, and percentage of T cells: each 1-log increase in
platelets at baseline was prognostic for improved 6-month survival; lower tumor burden was prognostic for hematologic
remission; and a higher percentage of CD3+ T-cells was prognostic for MRD response. Consistent with the BiTE
mechanism of action, higher percentage of CD45+ CD3+ CD8+ T cells was associated with hematologic remission
following blinatumomab. No examined biomarkers were signiﬁcant for the risk of grade ≥3 adverse events. Incorporating
baseline biomarkers into future studies may help to identify subgroups most likely to beneﬁt from blinatumomab.
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Patients with B-cell precursor acute lymphoblastic leukemia
(BCP-ALL) that relapses or is refractory to conventional
chemotherapy have a poor prognosis, with expected 1-year
survival rate of only 26% after ﬁrst salvage chemotherapy and
poorer survival outcomes associated with subsequent salvage
[1]. The pan-B cell marker CD19 is expressed in most
(>90%) B-lineage ALL cells, making it an ideal immunotherapy target for ALL [2, 3]. Blinatumomab is a BiTE®
(bispeciﬁc T-cell engager) molecule that simultaneously
engages CD19+ B cells and CD3+ cytotoxic T cells and
redirects T cells to lyse malignant and normal B cells [4, 5].
In the randomized, phase 3 TOWER study
(NCT02013167) in adults with advanced Ph– relapsed or
refractory BCP-ALL, blinatumomab was compared to
standard-of-care chemotherapy [6]. Patients in the blinatumomab group had signiﬁcantly longer overall survival,
compared with those in the chemotherapy group (median,
7.7 vs. 4.0 months; P = 0.01), as well as a signiﬁcantly
higher rate of hematologic remission—CR, CRh, or CR
with incomplete hematologic recovery (CRi) (44% vs. 25%;
P < 0.001).
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Hallmarks of the BiTE® immuno-oncology platform,
including T-cell activation, T-cell margination, redistribution, proliferation, and transient cytokine release, have been
extensively described and represent pharmacodynamic
characteristics of blinatumomab [7–14]. Given the increased
emphasis on personalized medicine in oncology, it is
becoming more important to ﬁnd genetic or cellular biomarkers to identify patients who will derive the greatest
beneﬁt from immunotherapy, including blinatumomab. The
objective of this post-hoc analysis was to identify baseline
laboratory and immunologic biomarkers in the TOWER
study that may be prognostic for clinical outcome, and to
identify factors associated with clinical outcomes in the
blinatumomab vs. chemotherapy group.

Materials and methods
Study design
The study design was described in detail in the primary
report [6]. This prospective, randomized, phase 3, activecontrolled study enrolled patients who were 18 years of age
or older with Ph– BCP-ALL that was refractory to primary
induction or salvage with intensive combination chemotherapy, in ﬁrst relapse with hematologic remission
lasting less than 12 months, in second or greater relapse, or
in relapse at any time after allogeneic stem cell transplantation. Patients were required to have more than 5% blasts
in the bone marrow and an Eastern Cooperative Oncology
Group performance status of 2 or less. All patients provided
written informed consent. The study protocol was conducted in accordance with the Declaration of Helsinki and
approved by the investigational review board or independent ethics committee at each study center. This study was
registered at ClinicalTrials.gov (Identiﬁer: NCT02013167).
Amgen funded this study. Qualiﬁed researchers may request
data from Amgen clinical studies. Complete details are
available at http://www.amgen.com/datasharing.
Patients were randomly assigned to receive open-label
treatment with either blinatumomab or standard chemotherapy in a 2:1 ratio. Randomization was stratiﬁed by
age (<35 vs. ≥35 years), previous salvage therapy, and
previous allogeneic stem cell transplantation. After two
cycles of induction therapy, patients in hematologic remission (≤5% bone marrow blasts) could receive up to three
cycles of consolidation therapy and up to 12 months of
maintenance therapy. At the discretion of the investigator,
protocol-speciﬁed therapy could be discontinued at any
time after the ﬁrst treatment cycle and the patient could
subsequently undergo stem cell transplantation.
Blinatumomab induction and consolidation therapy were
administered in 6 weeks cycles: 28 µg per day by continuous
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intravenous infusion for 4 weeks (with a lower dose of 9 μg
per day during week 1 of induction cycle 1 only) and no
treatment for 2 weeks. Blinatumomab maintenance was given
as a 4-week continuous infusion every 12 weeks. All patients in
the blinatumomab group received dexamethasone to prevent
cytokine release syndrome: (1) patients with a high tumor
burden during screening received dexamethasone 10 mg/m2/
day (up to 24 mg/day) orally or by intravenous infusion for up
to 21 days before the start of treatment; (2) patients without
high tumor burden at screening received dexamethasone 20 mg
by intravenous infusion within 1 h before each cycle of blinatumomab, before a dose increase, or after treatment interruption
for >4 h; (3) all patients received intrathecal prophylaxis for
central nervous system disease. Interruption or discontinuation
of the dose of blinatumomab was required if neurologic events
or other selected adverse events occurred. Dexamethasone was
administered (orally or intravenously) to patients with cytokine
release syndrome (maximum of 3 × 8 mg/day for up to 3 days,
then tapered over 4 days) or a neurologic event (maximum of
24 mg/day, then tapered over 4 days).
Patients in the chemotherapy group received the investigator’s choice of 1 of 4 regimens: ﬂudarabine, high-dose
cytosine arabinoside, and granulocyte colony-stimulating
factor (FLAG) with or without anthracycline; a high-dose
cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen; or a clofarabine-based regimen.
Dose adjustment was permitted for patients receiving standard chemotherapy but was not required for speciﬁc events.

Assessments
Complete remission was deﬁned as 5% or lower bone
marrow blasts and no other evidence of disease, with the
following peripheral blood counts: CR, platelets >100,000/
µL and absolute neutrophil count (ANC) > 1000/µL;
CRh, platelets > 50,000/µL and ANC > 500/µL; and CRi,
platelets > 100,000/µL or ANC > 1000/µL. A central
laboratory for study centers in the United States and Canada
assessed minimal residual disease (MRD) with multicolor
ﬂow cytometry and a central laboratory for other study
centers assessed MRD with real-time quantitative polymerase chain reaction of clonal immunoglobulin or T-cell
receptor gene rearrangements; assay sensitivity for MRD
was at least 10–4 [15, 16]. Investigators graded adverse
events according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0.

Baseline biomarkers
Bone marrow samples were analyzed for percentage of bone
marrow lymphoblasts. Blood samples at screening were
evaluated for the presence of the following baseline biomarkers, based on clinical and biological relevance:
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Table 1 Baseline characteristics.
Age, years, median (range)
<35, n (%)
≥35, n (%)

Blinatumomab (N = 271)

Chemotherapy (N = 134)

37 (18–80)

37 (18–78)

123 (45.4)

60 (44.8)

148 (54.6)

74 (55.2)

Male, n (%)

162 (59.8)

77 (57.5)

Primary refractory, n (%)

46 (17.0)

27 (20.1)

Prior salvage therapy, n (%)

164 (60.5)

80 (59.7)

Prior alloSCT, n (%)

94 (34.7)

46 (34.3)

Leukocytes (109/L)

271; 3.0 (1, 6)

134; 3.5 (2, 7)

Monocytes (109/L)

264; 0.1 (0.0, 0.3)

131; 0.1 (0.0, 0.3)

Neutrophils (109/L)

232; 1.2 (0.4, 2.7)

109; 1.5 (0.4, 3.0)

Lymphocytes (10 /L)

266; 0.8 (0.4, 1.4)

131; 0.8 (0.4, 1.8)

Granulocytes (/µL)

245; 1091 (383, 2 612)

85; 1157 (365, 2 893)

Platelets (109/L)

271; 49 (23, 103)

134; 52 (24, 133)

CD3+ T cells (%)

245; 64 (33, 82)

85; 56.5 (23, 81)

Baseline cell counts, n; median (Q1, Q3)

9

+

CD3 T cells (/µL)

245; 461 (253, 821)

85; 459 (268, 793)

245; 24.5 (11, 38)

85; 22 (10, 37)

CD45+ CD3+ CD4+ T cells (/µL)

245; 187 (88, 359)

85; 197 (100, 345)

CD45+ CD3+ CD8+ T cells (%)

245; 27 (14, 41)

85; 22 (13, 37)

245; 218 (109, 421)

85; 225 (105, 436)

CD45+ CD3+ CD4+ T cells (%)

+

+

+

CD45 CD3 CD8 T cells (/µL)
CD45+ CD3– CD19+ B cells (%)

245; 16 (2, 46)

83; 24 (4, 45)

CD45+ CD3– CD19+ B cells (/µL)

245; 113 (7, 586)

83; 123 (21, 747)

CD3– CD16+ CD56+ cells (%)

245; 7 (3, 14)

83; 7 (3, 10)

–

+

+

CD3 CD16 CD56 cells (/µL)

245; 69 (29, 142)

83; 69 (28, 155)

CD3+ :CD19+ (E/T) ratio cells in blood

214; 2.4 (0.5, 14)

75; 1.7 (0.5, 13)

% Bone marrow blasts

243; 80 (37, 93)

129; 80 (43, 93)

Percentage of lymphocytes were calculated by dividing absolute lymphocyte subset over total
lymphocyte count.
alloSCT allogeneic stem cell transplantation, Q quartile, E/T ratio effector-to-target ratio.

leukocytes, monocytes, neutrophils, lymphocytes, granulocytes, platelets, CD45+ CD3+ T cells absolute counts and
percentage, CD45+ CD3+ CD4+ T cells absolute counts
and percentage, CD45+ CD3+ CD8+ T cells absolute
counts and percentage, CD45+ CD3– CD19+ B cells
absolute counts and percentage, ratios of CD3+:CD19+
cells, and CD3– CD16+ CD56+ natural killer cells absolute
counts and percentage. Peripheral blood ﬂow cytometry
studies were gated on the entire CD45+ population, and
then gated on the side scatter deﬁned lymphocyte gate. The
percentage of lymphocyte subsets were calculated by multiplying the total lymphocyte count with the percentage of
cells with the designated lymphoid phenotype (Table 1).
Circulating cytokine levels were not measured.

Statistical analysis
In the screening phase, baseline biomarkers described above
were ﬁrst explored graphically and analyzed by univariate
model. In the univariate analysis, if the main effect or

treatment interaction between the biomarker and treatment had
a P value of 0.3 or lower, these selected biomarkers entered
the multivariate model to be analyzed for association with
treatment outcomes. Both percentages and counts for lymphocyte subsets were analyzed. A stepwise variable selection
was performed and an effect on outcome was determined to
stay in the ﬁnal multivariate model if either the main effect or
the interaction term between the biomarker and treatment had
a P value of 0.15 or lower. All biomarkers were treated as
continuous variables in the analysis. Prognostic and predictive
associations of baseline biomarkers with hematologic remission or MRD response were assessed by multivariate logistic
regression. Prognostic and predictive associations of baseline
biomarkers with overall survival, event-free survival, and
duration of response were assessed by multivariate Cox
regression. Prognostic biomarkers were those that deﬁned the
effects of patient or tumor characteristics on patient outcome
in both treatment groups; predictive biomarkers were those
that predicted patient outcome differently between treatment
groups. Predictive biomarkers were identiﬁed using interaction

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

tests with treatment group. Biomarkers were considered to be
prognostic (both groups) or predictive (one group) if the 95%
conﬁdence interval (CI) for the odds ratio (OR; hematologic
remission; MRD response) or the hazard ratio (HR; overall
survival) did not include 1. The effects of baseline biomarkers
on toxicity were determined by univariate logistic regression.

Results
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(Table 1). Median age was 37 years in each treatment
group; overall, 59% of patients were male. Many patients
were heavily pretreated for BCP-ALL before enrollment;
41% were treated in ﬁrst salvage and 59% in second or later
salvage. The proportion of patients treated with postallograft relapse was 35%. Median bone marrow blasts were
80% in each treatment group. The median ratio for CD3+:
CD19+ (T:B lymphocytes) was 2.4 (range, 0.5–14) in the
blinatumomab group and 1.7 (range, 0.5–13) in the
chemotherapy group.

Baseline characteristics
Overall survival
Patients were enrolled from January 2014 through September 2015. A total of 405 patients received blinatumomab
(n = 271) or chemotherapy (n = 134). Demographics,
baseline disease characteristics, and baseline cell counts
were generally balanced between the treatment groups

We ﬁrst sought to correlate baseline disease burden, bone
marrow function, and effector T-cell numbers with survival
outcome. A Cox regression analysis for overall survival was
performed (Fig. 1a), where lower HR represented improved

A
Leukocytes (109/L)a
Effect
Granulocytes (/µL)a
Effect
Platelets (109/L)a
Effect
CD45+ CD3– CD19+ B cells (%)
Treatment interaction
Blinatumomab
Chemotherapy
Bone marrow blasts (%)
Effect

P Values

Hazard Ratio and 95% CI

0.8537

1.038 (0.699–1.542)

0.0397

0.752 (0.574–0.987)

<0.0001

0.433 (0.288–0.650)

0.0145
1.188 (1.093–1.292)
1.033 (0.928–1.151)
0.2070

1.036 (0.981–1.094)
0.1

1
Improved Overall Survival

10
Decreased Overall Survival

B
P Values

Hazard Ratio and 95% CI

0.0484

1.041 (1.000–1.082)

Bone marrow blasts (%)
Effect
CD3+ (%)
Treatment Interaction

0.1141

Blinatumomab

0.929 (0.883–0.978)

SOC Chemotherapy

0.988 (0.929–1.050)
1
0.1
10
Improved Event-free Survival
Decreased Event-free Survival

C

P Values

Hazard Ratio and 95% CI

0.1106

0.569 (0.285–1.137)

0.0620

0.790 (0.616–1.012)

Platelets (109/L LOG10 Transformed)
Effect
CD3– CD16/56+ (%)
Effect

0.1
10
1
Improved Duration of Response
Decreased Duration of Response

Fig. 1 Baseline biomarkers evaluated for association with overall
survival, event-free survival, and duration of response. a Overall
survival. b Event-free survival. c Duration of response. For overall
survival, a hazard ratio of <1 indicates that higher levels of the

biomarker were prognostic or predictive for improved overall survival.
a
LOG10 transformed. CD45+ CD3− CD19+ B cells are expressed as a
percentage of circulating lymphocytes. Bone marrow blasts are a
percentage of all nucleated marrow cells. CI conﬁdence interval.
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6-Month Survival Probability

A
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Blinatumomab
SOC

0

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Effect

0.5

survival. No relationship was shown between morphologically determined bone marrow blast percentage and survival
(HR, 1.04; 95% CI, 0.98–1.09). In contrast, a higher proportion of CD45+ CD3– CD19+ B cells at baseline was
predictive and associated with inferior overall survival in
the blinatumomab group (HR, 1.19; 95% CI, 1.09–1.29) but
not in the chemotherapy group (HR, 1.03; 95% CI,
0.93–1.15) (Fig. 2a). In terms of baseline bone marrow
function, a higher platelet (HR, 0.43; 95% CI, 0.29–0.65) or
granulocytes (HR, 0.75; 95% CI, 0.57–0.99) was prognostic
for improved overall survival. For each 1-log increase in
platelets at baseline, 6-month survival probability increased
by ~30% (Fig. 2b). Preliminary univariate analyses for all
biomarkers are included in Supplementary Materials
Table S1.

Event-free survival
No strong predictive or prognostic biomarkers were identiﬁed for event-free survival in the multivariate analysis
(Fig. 1b). In the multivariate analysis for improved eventfree survival, the HR for lower percentage of baseline bone
marrow blasts was 1.04 (95% CI, 1.0–1.08). The HR for
higher percentage of CD3+ T cells at baseline was 0.93
(95% CI, 0.88–0.98) in the blinatumomab group and 0.99
(95% CI, 0.93–1.05) in the chemotherapy group. Univariate
analyses for all biomarkers are included in Supplementary
Materials Table S2.

20%
40%
60%
80%
Percentage of CD45+ CD3– CD19+ Cells

B
6-Month Survival Probability

Fig. 2 Baseline biomarkers
and 6-month survival
probabilities. a A lower
percentage of CD45+ CD3−
CD19+ B lymphocytes at
baseline was associated with
higher 6-month survival
probability in the blinatumomab
group; this association was less
pronounced in the chemotherapy
(SOC) group. b For both
treatment groups combined,
higher platelet counts at baseline
were associated with higher 6month survival probability.
a
LOG10 transformed.
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1.0

1.5
Platelets (109/L)a

2.0

2.5

Duration of response
No predictive or prognostic biomarkers were identiﬁed for
duration of response in the multivariate analysis (Fig. 1c).
Univariate analyses from the screening phase for all biomarkers are included in Supplementary Materials Table S3.

Hematologic remission
In the primary analysis of TOWER, the hematologic
remission rates for blinatumomab and chemotherapy were
43.9% vs. 24.6%, respectively (P < 0.001), with CR in
33.6% vs. 15.7%, CRh in 8.9% vs. 4.5%, and CRi in 1.5%
vs. 4.5% of patients [6]. In a univariate analysis of baseline
biomarkers, patients who achieved hematologic remission
with blinatumomab or chemotherapy compared with those
who did not, had lower baseline bone marrow disease
burden and a higher percentages of total T cells, T helper
and T suppressor cells, characterized by CD45+ CD3+
T cells, CD45+ CD3+ CD4+ T cells, and CD45+ CD3+
CD8+ T cells, respectively (Fig. 3). In both treatment
groups, the baseline E:T ratio was higher in patients
achieving hematologic remission compared with patients
without hematologic remission.
As increased number of prior lines of therapy negatively
inﬂuence BCP-ALL outcomes [17, 18], we looked for differences in the tumor burden or immune status of patients
treated in ﬁrst vs. second or later salvage therapy.
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Exploratory analysis suggests lower baseline bone marrow
blasts and CD19+ cells were associated with higher hematologic remission rate for both blinatumomab and

chemotherapy groups in ﬁrst salvage as well as in second or
later salvage (Fig. 4). In contrast, the association between
immune proﬁle and hematologic remission differed between
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Fig. 3 Relationship between baseline biomarkers and hematologic
remission during blinatumomab (BLIN) or chemotherapy (SOC).
Percentage of (a) bone marrow (BM) blasts, (b) CD3+ CD4+ T cells,
(c) CD3+ CD8+ T cells, (d) CD19+ B cells, and (e) CD3+ T cells at
baseline in patients with (CR+) or without (Non CR+) hematologic
remission (CR, CRh, and CRi). f Baseline CD3+:CD19+ (E:T) ratio in
patients with or without hematologic remission. The red horizontal line
indicates the median value and the box includes the 25th and 75th
percentile values. CR complete remission with full hematologic
recovery, CRh complete remission with partial hematologic recovery,
CRi complete remission with incomplete hematologic recovery, SOC
standard of care.

blinatumomab and chemotherapy for treatment in ﬁrst salvage. Patients treated with blinatumomab had a higher
hematologic remission rate at ﬁrst salvage if there was a
higher proportion of CD3+ CD4+ T cells or CD3+ CD8+
T cells, as well as a higher E:T ratio at baseline, whereas
this association was weaker for patients treated with chemotherapy. Therefore, immune status appeared to be predictive of response to blinatumomab for patients treated at
ﬁrst salvage.
In the multivariate regression analysis (Fig. 5a), a lower
percentage of bone marrow blasts at baseline (OR, 0.87;
95% CI, 0.80–0.95) was prognostic for hematologic
remission, and platelet count at baseline was not prognostic
(OR, 1.64; 95% CI, 0.90–2.99). A higher CD45+ CD3+
CD8+ T-cell percentage at baseline was predictive and
associated with hematologic remission in the blinatumomab
group (OR, 1.44; 95% CI, 1.22–1.70) but not in the chemotherapy group (OR, 1.06; 95% CI, 0.82–1.38). Absolute
numbers of T-cells at baseline were not found to correlate
with response to blinatumomab (Table S4). Preliminary
univariate analyses in the screening phase for all biomarkers
are included in Supplementary Materials Table S4.

MRD response
In a multivariate regression analysis for determinants of
MRD response (Fig. 5b), a higher percentage of CD3+
T cells in blood at baseline was prognostic for MRD
response (OR, 1.25; 95% CI, 1.13–1.38). Univariate analyses in the screening phase for all biomarkers are included
in Supplementary Materials Table S5.

Adverse events
In the univariate logistic regression analysis for adverse
events of grade ≥3 neurologic events, grade ≥3 infections, or
grade ≥3 cytokine release syndrome, none of the examined
biomarkers were signiﬁcant for either treatment group,
including percentage of bone marrow blasts, blast count,
absolute count of CD45+ CD3+ CD8+ cells, percentage of
CD45+ CD3+ CD8+ cells, absolute count of CD3+ cells,
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percentage of CD3+ cells, absolute count of CD3− CD19+
cells and percentage of CD3− CD19+ cells (Table 2). The
results of each biomarker in this analysis are summarized in
Table 3.

Discussion
In this biomarker analysis, clinically relevant baseline
laboratory markers associated with survival outcome after
blinatumomab or chemotherapy in patients with BCP-ALL
were examined. We found that higher granulocytes and
platelet counts were prognostic for improved overall survival in either treatment group. The strongest predictive
marker for improved overall survival after blinatumomab
was a lower percentage of peripheral blood CD45+ CD3−
CD19+ B lymphocytes. No strong predictive or prognostic
markers for event-free survival and duration of response
were identiﬁed.
For biomarkers of hematologic remission, a multivariate
analysis revealed that a lower percentage of bone marrow
blasts at baseline was prognostic in either treatment group.
This is consistent with the notion that treating patients with
lower disease burden may result in a higher treatment
response. Thus, conﬁrming that this hypothesis applies to
patients treated with either immunotherapy or chemotherapy. Furthermore, higher baseline platelet count was also
prognostic for response to therapy, suggesting this biomarker may function as a surrogate of preserved bone
marrow function. Consistent with the blinatumomab mode
of action, a higher baseline percentage of CD3+ CD8+
effector T cells was a predictive marker of response to
blinatumomab but not chemotherapy. Although blinatumomab can eradicate tumors at low effector-to-target (E:T)
cell ratios through serial lysis [7, 19, 20], greater percentages of CD3+ T cell with correspondingly lower percentages of CD19+ B cells (i.e., lower tumor burden) create the
optimal tumor-killing environment [8]. In this and other
studies, absolute numbers of T-cells at baseline were not
found to correlate with response to blinatumomab [5, 7, 10].
In a single-arm, phase 2 study of adults with relapsed or
refractory BCP-ALL, 43 of 59 (73%) patients with <50%
blasts at baseline and 38 of 130 (29%) patients with ≥50%
blasts at baseline achieved hematologic remission [8]. In the
randomized, phase 3 TOWER study, the OR for hematologic remission with blinatumomab compared with chemotherapy was 3.65 (95% CI, 1.63–8.17) in patients with
<50% blasts at baseline and 1.99 (95% CI, 1.12–3.55) in
patients with ≥50% blasts at baseline [6]. In the original
TOWER study, overall survival was generally consistent
across subgroups, including blasts at baseline. These previous results, combined with the ﬁndings from the multivariate models of this biomarker analysis, suggest that
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Fig. 4 Relationship between baseline biomarkers and hematologic
remission during blinatumomab (BLIN) or chemotherapy (SOC)
as ﬁrst salvage therapy or as second or later salvage therapy.
Percentage of (a) bone marrow (BM) blasts, (b) CD3+ CD4+ T cells,
(c) CD3+ CD8+ T cells, (d) CD19+ B cells, and (e) CD3+ T cells at
baseline in patients with (CR+) or without (Non CR+) hematologic
remission (CR, CRh, and CRi). f Baseline CD3+:CD19+ (E:T) ratio in
patients with or without hematologic remission. The red horizontal line
indicates the median value and the box includes the 25th and 75th
percentile values. CR complete remission with full hematologic
recovery, CRh complete remission with partial hematologic recovery,
CRi complete remission with incomplete hematologic recovery, SOC
standard of care.

cytoreduction or debulking treatment to reduce blast counts
before initiating blinatumomab in adults with relapsed or
refractory BCP-ALL could increase hematologic remission
rates but may not have a signiﬁcant effect on overall
survival.
Other results from this study suggested that if another
treatment is used before an immunotherapeutic such as blinatumomab, then a prior treatment that maintains the number and ﬁtness of T cells would be preferred. A higher
percentage of CD45+ CD3+ CD8+ T-cells at baseline was
predictive for hematologic remission in the blinatumomab
group of this study. The baseline CD45+ CD3+ CD8+ T-cell
A
9

percentage was not predictive for hematologic remission in
the chemotherapy group, suggesting that the number of
T cells at baseline might be an important biomarker for
response to immunotherapy-based drugs such as blinatumomab, but not chemotherapy. Zhu et al. [14] also
demonstrated that patients who had a higher percentage of
T cells and a lower percentage of B cells at baseline
responded better to blinatumomab. In another study, patients
who responded to blinatumomab had more pronounced Tcell expansion, which was associated with proliferation of
CD4+ and CD8+ T cells and memory subsets [7].
In this biomarker analysis, higher CD3+ T-cell percentage were prognostic for a higher likelihood of MRD
negativity in either treatment group, with no predictive
factor for differential MRD response between treatment
groups identiﬁed. These ﬁndings are corroborated by Zugmaier et al. [12], who showed that long-term survivors
(≥30 months) were MRD negative and had greater CD3+ Tcell expansion.
This biomarker analysis did not identify a prognostic or
predictive factor for severe (grade ≥ 3) neurologic events,
infections, or cytokine release syndrome. Thus, no biomarker for blinatumomab adverse events was identiﬁed. In
contrast, these results are different compared with other

P Values

Hazard Ratio and 95% CI

0.1031

1.643 (0.904–2.986)

a

Platelets (10 /L)
Effect

CD45+ CD3+ CD8+ T cells (%)
Treatment interaction

0.0510

Blinatumomab

1.441 (1.222–1.700)

Chemotherapy

1.063 (0.818–1.382)

Bone marrow blasts (%)
Effect

0.871 (0.803–0.945)

0.0008
0.1

1
Decreased Likelihood
of Remission

10
Increased Likelihood
of Remission

B
P Values

Hazard Ratio and 95% CI

0.0542

1.745 (0.990–3.076)

<0.0001

1.245 (1.126–1.377)

CD3+ T cells (/µL)a
Effect
CD3+ T cells (%)
Effect

0.1

10

1
Decreased Likelihood
of MRD Response

Fig. 5 Baseline biomarkers evaluated for association with hematologic remission and minimal residual disease. a Hematologic
remission. b minimal residual disease (MRD) response. When the
odds ratio was >1, the biomarker was prognostic or predictive for
increased likelihood of hematologic remission or MRD response. CR/
CRh/CRi = complete remission with full (CR), partial (CRh), or

Increased Likelihood
of MRD Response

incomplete (CRi) recovery of peripheral blood counts. MRD response
= an MRD level below 10−4 (by PCR or ﬂow cytometry). aLOG10
transformed. T cells are expressed as a percentage of circulating
lymphocytes. Bone marrow blasts are a percentage of all nucleated
marrow cells. CI conﬁdence interval, PCR polymerase chain reaction.
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Table 2 Odds ratios for adverse
events of interest by baseline
biomarker.

Adverse Event of Interest
Biomarker
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Blinatumomab
Odds Ratio (95% CI)

Chemotherapy
Odds Ratio (95% CI)

1.00 (0.99–1.02)

1.00 (0.99–1.02)

Grade ≥3 neurologic events
Bone marrow blast (%)
9

Blast count (10 /L)

0.97 (0.90–1.04)

0.96 (0.84–1.09)

CD45+ CD3+ CD8+ cells (%)

0.99 (0.97–1.02)

1.00 (0.97–1.03)

CD45+ CD3+ CD8+ cell counts (/µL)

1.00 (1.00–1.00)

1.00 (1.00–1.00)

CD3+ (%)

0.99 (0.98–1.01)

1.00 (0.98–1.01)

CD3+ cell counts (/µL)

1.00 (1.00–1.00)

1.00 (1.00–1.00)

CD3−CD19+ (%)

1.01 (1.00–1.03)

0.99 (0.96–1.02)

CD3−CD19+ cell counts (/µL)

1.00 (1.00–1.00)

1.00 (1.00–1.00)

Grade ≥3 infections
Bone marrow blast (%)

1.00 (0.99–1.01)

1.01 (1.00–1.02)

Blast count (109/L)

0.99 (0.98–1.01)

1.01 (0.98–1.05)

CD45+ CD3+ CD8+ cells (%)

0.99 (0.97–1.00)

1.01 (0.99–1.03)

CD45+ CD3+ CD8+ cell counts (/µL)

1.00 (1.00–1.00)

1.00 (1.00–1.00)
1.00 (0.99–1.01)

+

CD3 (%)

0.99 (0.98–1.00)

CD3+ cell counts (/µL)

1.00 (1.00–1.00)

1.00 (1.00–1.00)

CD3− CD19+ (%)

1.00 (1.00–1.01)

1.02 (1.00–1.03)

CD3− CD19+ cell counts (/µL)

1.00 (1.00–1.00)

1.00 (1.00–1.00)

Bone marrow blast (%)

1.02 (1.00–1.05)

–

Blast count (109/L)

0.99 (0.93–1.05)

–

CD45+ CD3+ CD8+ cells (%)

1.02 (1.00–1.05)

–

CD45+ CD3+ CD8+ cell counts (/µL)

1.00 (1.00–1.00)

–

Grade ≥3 cytokine release syndrome

+

CD3 (%)

1.03 (1.00–1.05)

–

CD3+ cell counts (/µL)

1.00 (1.00–1.00)

–

CD3− CD19+ (%)

0.99 (0.96–1.01)

–

CD3− CD19+ cell counts (/µL)

1.00 (1.00–1.00)

–

T cells were measured as a percentage of all lymphocytes in the blood.
CI conﬁdence interval.

Table 3 Summary of prognostic
(both treatment groups) or
predictive (either treatment
groups).

Outcome
Improved overall survival

Increased likelihood of CR/CRh/
CRi
Increased likelihood of MRD
response
Adverse events of interest

Baseline biomarker

Finding

Higher neutrophil count

Prognostic

Higher platelet count

Prognostic

Lower percentage of CD45+ CD3– CD19+ cells

Predictive
(blinatumomab)

Lower percentage of bone marrow blasts

Prognostic

+

+

+

Higher percentage of CD45 CD3 CD8 T cells in
ﬁrst salvage

Predictive
(blinatumomab)

Higher percentage of CD3+ T cell cells

Prognostic

Percentage of bone marrow blasts

None

Percentage of CD45+ CD3+ CD8+ cells

None

Percentage of CD3+ cells

None

CR complete remission with full hematologic recovery, CRh complete remission with partial hematologic
recovery, CRi complete remission with incomplete hematologic recovery, MRD minimal residual disease.
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publications in patients undergoing CD19 chimeric antigen
receptor (CAR) T-cell therapy where serum cytokines were
found to be associated with neurotoxicity [21, 22]. However, these discrepancies can be explained by the different
platforms and methods used to measure cytokines, including differences in sensitivity and timepoints for cytokine
analysis, as well as the high number of CAR T-cells
reinfused.
It should be noted that this descriptive analysis of biomarkers should be considered exploratory, and it was not
considered in the original study design or sample size calculations for the TOWER clinical trial. Dexamethasone
premedication in a selected subgroup of patients may have
altered the number and function of T cells after baseline
levels were assessed. Thus, the observed associations
between baseline blast count and hematologic remission
with blinatumomab or chemotherapy may have been
inﬂuenced by the intervening use of dexamethasone. Lastly,
measuring plasma cytokine concentrations may be warranted in future studies.
In conclusion, this analysis of a large, phase 3 comparison of blinatumomab or chemotherapy for salvage therapy
in adults with relapsed or refractory BCP-ALL identiﬁed
baseline biomarkers that may be prognostic or predictive for
clinical outcomes, including overall survival, hematologic
remission, and MRD response. No examined biomarker was
signiﬁcant for adverse events. Although these studies have
identiﬁed potential prognostic and predictive associations
with blinatumomab therapy, validation in a prospective
study is needed to conﬁrm patient subgroups most likely to
beneﬁt from blinatumomab.
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